Mangoceuticals (MGRX) Competitors $2.57 +0.32 (+14.22%) Closing price 04:00 PM EasternExtended Trading$2.46 -0.11 (-4.28%) As of 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGRX vs. ATPC, PIII, BDSX, EUDA, BMGL, CCM, MRAI, BRTX, BGLC, and SSYShould you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Agape ATP (ATPC), P3 Health Partners (PIII), Biodesix (BDSX), EUDA Health (EUDA), Basel Medical Group (BMGL), Concord Medical Services (CCM), Marpai (MRAI), Biorestorative Therapies (BRTX), BioNexus Gene Lab (BGLC), and SunLink Health Systems (SSY). These companies are all part of the "healthcare" industry. Mangoceuticals vs. Its Competitors Agape ATP P3 Health Partners Biodesix EUDA Health Basel Medical Group Concord Medical Services Marpai Biorestorative Therapies BioNexus Gene Lab SunLink Health Systems Agape ATP (NASDAQ:ATPC) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Does the media favor ATPC or MGRX? In the previous week, Agape ATP had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Agape ATP and 0 mentions for Mangoceuticals. Agape ATP's average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score. Company Overall Sentiment Agape ATP Neutral Mangoceuticals Neutral Do insiders & institutionals believe in ATPC or MGRX? 0.0% of Agape ATP shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 9.7% of Agape ATP shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, ATPC or MGRX? Agape ATP has higher revenue and earnings than Mangoceuticals. Agape ATP is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgape ATP$1.32M48.12-$2.47M-$0.41-3.10Mangoceuticals$620K43.69-$8.71M-$3.86-0.67 Is ATPC or MGRX more profitable? Agape ATP has a net margin of -183.13% compared to Mangoceuticals' net margin of -2,757.86%. Agape ATP's return on equity of -20.32% beat Mangoceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agape ATP-183.13% -20.32% -18.55% Mangoceuticals -2,757.86%-85.01%-78.08% Which has more volatility and risk, ATPC or MGRX? Agape ATP has a beta of -0.98, indicating that its share price is 198% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. SummaryAgape ATP beats Mangoceuticals on 8 of the 12 factors compared between the two stocks. Get Mangoceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGRX vs. The Competition Export to ExcelMetricMangoceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.09M$2.52B$5.79B$10.49BDividend YieldN/A55.04%5.61%4.57%P/E Ratio-0.6723.26348.8926.87Price / Sales43.69563.62522.55164.30Price / CashN/A27.8326.0131.15Price / Book0.605.3615.536.50Net Income-$8.71M$32.95M$3.29B$271.42M7 Day Performance20.66%3.96%200.87%3.69%1 Month Performance48.55%5.27%184.38%8.07%1 Year Performance-95.43%-0.72%325.51%29.65% Mangoceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGRXMangoceuticals0.2745 of 5 stars$2.57+14.2%N/A-96.0%$27.09M$620K-0.673Gap DownATPCAgape ATP0.1896 of 5 stars$1.30+1.2%N/A-32.8%$64.01M$1.32M-3.1640PIIIP3 Health Partners2.7129 of 5 stars$8.38-2.9%$16.25+93.9%-61.7%$62M$1.50B-0.18500BDSXBiodesix3.6874 of 5 stars$6.56-13.7%$35.00+433.5%-80.2%$55.72M$71.32M-1.13220Positive NewsAnalyst ForecastEUDAEUDA Health0.4081 of 5 stars$1.10+3.8%N/A-68.3%$39.39M$4.01M0.002Gap UpBMGLBasel Medical GroupN/A$2.07+4.5%N/AN/A$36.54MN/A0.0036Positive NewsCCMConcord Medical Services1.2702 of 5 stars$5.65-1.1%N/A+6.4%$24.79M$52.60M0.00970MRAIMarpaiN/A$1.11-8.3%N/A+96.2%$19.17M$34.87M-0.42150High Trading VolumeBRTXBiorestorative Therapies1.1913 of 5 stars$1.48-2.0%N/A-24.5%$12.05M$400K-1.177BGLCBioNexus Gene Lab0.1363 of 5 stars$5.22+4.0%N/A+33.0%$9.02M$9.51M0.0030Positive NewsSSYSunLink Health SystemsN/A$1.12+16.6%N/A+26.5%$7.88M$31.09M4.661,376Gap Up Related Companies and Tools Related Companies ATPC Alternatives PIII Alternatives BDSX Alternatives EUDA Alternatives BMGL Alternatives CCM Alternatives MRAI Alternatives BRTX Alternatives BGLC Alternatives SSY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGRX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe next AI Hype Spike is days away — don’t miss itOn this date, AI could trigger the kind of predictable surge that's already paid out 61%… 158%… and even 382% ...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGRX Stock Alerts